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BACKGROUND: Tumoural interstitial hypertension, possibly modulated by platelet-derived and vascular endothelial growth factor
receptors (PDGFR and VEGFR), may mediate resistance to chemotherapy.
METHODS: Forty-eight patients with advanced solid tumours received oral PDGFR inhibitor CP-868,596 (60–100mg twice daily
(BID)) and docetaxel (75–100mgm
–2), or CP-868,596 (60mg BID), docetaxel (75mgm
–2), and VEGFR inhibitor axitinib
(5mg BID).
RESULTS: The CP-868,596/docetaxel was escalated as above. The CP-868,596/docetaxel/axitinib was not dose escalated because of
increased incidence of mucositis-like adverse events (AEs) with concurrent neutropenia relative to that expected for docetaxel. All
tested regimens were tolerable, including 100mg BID CP-868,596 (recommended phase II dose) plus 100mgm
–2 docetaxel
(maximum approved dose). Most treatment-emergent AEs were mild–moderate and reversible, commonly including nausea,
diarrhoea, vomiting, constipation, fatigue, and anaemia (CP-868,596/docetaxel), and hypertension, lethargy, diarrhoea, and fatigue
(CP-868,596/docetaxel/axitnib). Pharmacokinetics were unaffected by co-administration. Twenty-one patients achieved stable
disease, including all seven evaluable on CP-868,596/docetaxel/axitinib. All nine CP-868,596/docetaxel/axitinib patients received
therapy for a median of six (range, 3–16) cycles.
CONCLUSIONS: The CP-868,596/docetaxel was well tolerated, but increased efficacy was not observed. Addition of axitinib delivered
greater benefits than expected in the number of patients achieving prolonged stable disease with a moderate increase in AEs.
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Progression of tumours requires angiogenesis, driven by vascular
endothelial growth factor (VEGF), to form new capillary networks.
Subsequently, platelet-derived growth factor (PDGF) activation of
the tyrosine kinase PDGF receptor-b (PDGFR-b) is responsible for
the migration of supporting pericytes to stabilise this network
(Hellstrom et al, 1999; Saharinen and Alitalo, 2003) and also for
increased endothelial cell VEGF expression (Hellstrom et al, 1999;
Wang et al, 1999; Pietras et al, 2003a).
Tumoural blood vessels have variable diameters, sparse pericyte
coverage, and are leaky to solutes (Saharinen and Alitalo, 2003). In
addition, excessive PDGF production within tumours stimulates
stromal cells via collagen-binding integrin-a2b1 (Reed et al, 1997;
Pietras et al, 2001; Ostman and Heldin, 2007). Overall, these factors
contribute to an increase of the interstitial fluid pressure (IFP)
within tumours, resulting in tumoural interstitial hypertension
(TIH). The TIH reduces the hydrostatic gradient from capillary to
tissues and decreases the diffusion of molecules, including drugs,
into tumours (Gullino et al, 1964; Jain, 1987), with therapeutic
consequences.
The PDGFR-b is commonly overexpressed in the stroma and
pericytes of several solid organ tumour types (Reed et al, 1997;
Ostman and Heldin, 2007). Preclinical data have shown that
PDGFR inhibition reduces tumoural IFP and increases the
intracellular concentrations of cytotoxics (Pietras et al, 2001,
2003b; Vlahovic et al, 2006). The VEGF inhibition has also been
shown to reduce tumour IFP (Willett et al, 2005). Thus, concurrent
modulation of both angiogenesis and TIH may achieve improved
tumoural drug exposure and increase therapeutic efficacy. Never-
theless, the potential of simultaneously inhibiting these targets has
not been assessed clinically.
The CP-868,596 is a potent, oral, selective inhibitor of PDGFR-b
tyrosine kinase, with an IC50 of 0.4ngml
–1 and is 450–100-fold
more selective for PDGFR vs other related kinases (Lewis et al,
2009). The first-in-human phase 1 study of single-agent
CP-868,596 identified a recommended dosage of 100mg twice
daily (BID) with food (Lewis et al, 2009). Dose-limiting toxicities
(DLTs) identified included haematuria, transaminitis, insomnia,
and nausea/vomiting. The majority of adverse events (AEs) were of
mild or moderate severity, with nausea and vomiting – which were
mitigated by administration with food – most commonly reported.
Studies in xenograft models have suggested that the cytotoxicity
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sof docetaxel and gemcitabine are increased by combination with
CP-868,596 (Whalen et al, 2005). In order to understand the
clinical effects of combining PDGFR inhibition with chemo-
therapy, this phase Ib trial evaluated the safety and efficacy of the
combination of CP-868,596 and docetaxel. Also explored was
the effect of concurrently inhibiting PDGFR and VEGF receptors
(VEGFRs) by adding axitinib (AG-013736), a potent and selective
oral inhibitor of VEGFR-1, -2, and -3, to the combination.
PATIENTS AND METHODS
Patient selection
Eligible patients had the following: (1) histologically/cytologically
proven solid organ tumours refractory/resistant to therapy;
(2) ECOG performance status 0–2; (3) adequate organ function
– absolute neutrophil count X1.5 10
9 per l, platelets X100 10
9
per l, haemoglobin X8.5g per 100ml, serum creatinine p1.5 
upper limit of normal (ULN), total serum bilirubin pULN,
aspartate aminotransferase/alanine aminotransferase p1.5 ULN,
urine protein o1þ on urinalysis or 24-h urine protein o500mg
if initial urine protein X1þ, QTc p500ms; and (4) for patients
receiving axitinib – baseline blood pressure o140/90mmHg.
Patients were excluded for the following: (1) history of grade X2
haemoptysis or grade 1 haemoptysis within 30 days of study entry;
(2) surgery within 4 weeks of entry; (3) prior systemic therapy
within 3 weeks of entry; (4) anticoagulant therapy; (5) use of
cytochrome CYP3A4 or P-glycoprotein inhibitors within 1 week, or
inducers within 3 weeks of entry; (6) cardiac history including
prolonged QTc interval or deep-vein thrombosis within 3 months
of entry; and (7) for patients receiving axitinib – central lung
lesions involving major vessels and previous therapy with
antiangiogenesis agents.
Study design
This was a multicenter dose-escalation phase Ib study of
CP-868,596 plus docetaxel þ/  axitinib. Study design is available
online (Supplementary Figure 1). The primary objective was to
define the maximum tolerated dose of the double and triple
combinations. However, should dose levels (DLs) combining the
recommended phase 2 doses of investigational agents (CP-868,596
or axitinib) with approved doses of docetaxel be well tolerated,
dose escalation would stop at this point and the relevant DL(s)
expanded for further pharmacodynamic and efficacy studies.
The primary end point was DLTs occurring on combination
therapy during the first-treatment cycle, assessed using the
National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTCAE), version 3.0. The DLTs were defined
as (1) grade 4 neutropenia for 47 days; (2) febrile neutropenia
requiring intravenous (IV) antibiotics; (3) grade 4 thrombocyto-
penia for 47 days or with bleeding requiring transfusion;
(4) grade X3 clinically significant non-haematologic toxicity for
47 days despite appropriate treatment; and (5) inability to begin
cycle 2 within 2 weeks of scheduled dosing because of persistent
4grade 1 toxicity.
Dose escalation was allowed if none of the three or one of
six patients experienced a DLT on combination therapy during
cycle 1. The DLs could be expanded based on adequate safety/
tolerability and provision was made for dose de-escalation in the
event of DLTs in X2 of three or six patients.
The MTD was defined as the highest DL at which o33%
of patients experienced a DLT within days 22–42 of cycle 1
(DLs 1–3) or days 1–28 of cycle 1 (DL 4). Sample size was
determined empirically depending on safety/tolerability.
The study was performed in accordance with International
Conference on Harmonization Good Clinical Practice guidelines,
and institutional ethics committee approval was obtained. All
participants provided written consent.
Treatment
Patients were enrolled into four dose-escalation DLs of 3–6 patients.
Patients enrolled into DLs 1–3 received CP-868,596 orally BID plus
docetaxel once every 21 days (starting day 22 of cycle 1). Patients
enrolled into DL 4 received CP-868,596 BID plus axitinib 5mg BID
plus docetaxel once every 21 days (starting day 8 of cycle 1).
Each cohort included a lead-in phase. In DLs 1–3, the lead-in
phase was 21 days, such that cycle 1 was 42 days. The lead-in phase
allowed for CP-868,596 steady-state pharmacokinetics and phar-
macodynamic studies (biomarkers and dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI) tumoural
analysis). During the lead-in phase, patients received CP-868,596
100mg BID on an empty stomach over 14 days with a 5-HT3
antagonist, followed by a cohort dose of CP-868,596 BID (60 or
100mg), given with food.
In DL 4, the lead-in phase was 7 days, such that cycle 1 was 28
days. The lead-in phase allowed for CP-868,596 and axitinib
to potentially ‘normalise’ tumour vasculature (Jain, 2005). During
the lead-in phase, patients received CP-868,596 60mg BID plus
axitinib (5mg BID), given with food.
For all cohorts, docetaxel (75 or 100mgm
–2 IV over 1h) was
administered after the lead-in phases and then every 21 days.
Premedication was standard.
Evaluation of safety and tolerability
All patients who received at least one dose of study medication
(CP-868,596 or axitinib) were evaluable for safety. Safety data were
collected prospectively. The AEs were graded according to NCI
CTCAE, version 3.0. The ECGs were performed at baseline and 3h
post-docetaxel therapy in cycle 1. Symptomatic QTc prolongation
required discontinuation from the study. The safety evaluation
period extended from the last dose of study drug through 28 days’
follow-up.
Antitumour activity
All patients who received study treatment and had measurable
disease at baseline were evaluable for response using response
evaluation criteria in solid tumours (Therasse et al, 2000).
Radiological assessments were conducted at screening and within
7 days prior to cycle 1 docetaxel dose for DLs 1–3, and at
screening and cycle 2 day 1 for DL 4. Subsequent assessments were
every other cycle for all DLs.
Pharmacokinetic methods and analyses
In DLs 1–3, blood samples for determination of trough CP-868,596
serum concentrations were taken from all patients predose (0h) on
day 14. For the MTD expansion cohort (DL 2), blood samples were
collected for the pharmacokinetic profiling of CP-868,596 alone
and for the combination CP-868,596 plus docetaxel: samples were
taken during cycle 1 at 0h (predose) and 0.5, 1, 1.25, 1.75, 3, 6.5,
and 12h post-dose on days 21 (CP-868,596) and 22 (CP-868,596
and docetaxel). For CP-868,596 and docetaxel, 24- and 48-h
post-dose samples were collected on days 23 and 24, respectively.
In DL 4, sampling was conducted on day 8 (CP-868,596, axitinib,
and docetaxel) and day 9 (CP-868,596 and axitinib) of cycle 1:
samples were collected at 0h (predose) and 1, 1.75, 3, 4.5, and 6.5h
post-dose on day 8 and at 0h (predose) on day 9 for CP-868,596
and axitinib. Docetaxel concentrations were assessed at 1 (end of
infusion), 1.75, and 6.5h post-dose on day 8.
Concentrations of CP-868,596, docetaxel, and axitinib were
determined using validated HPLC/tandem mass spectrometry
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s(HPLC/TMS) methods. Analytes were detected using an Applied-
Biosystem Sciex API 3000/4000 LC/TMS system (MDI SCIEX,
Concord, ON, Canada) operating in positive ion Electrospray
mode. Non-compartmental pharmacokinetic analysis was per-
formed using WinNonlin, version 3.2 (Pharsight, Mountain View,
CA, USA). Parameters estimated for CP-868,596 and axitinib
included maximum observed plasma concentration (Cmax), time to
Cmax (Tmax), and area under the plasma concentration–time curve
from time zero to the dosing interval (AUC0–tau), and for
docetaxel: Tmax, half-life (t1/2), AUC0–48, and AUC0–infinity.
Pharmacodynamic assessments
The DCE-MRI was performed between days –3 and 0, and days 10
and 14, in a subset of patients in DL 2. A 3-T unit was used with a
torso-phased array for imaging and a three-dimensional fast
spoiled gradient-recalled echo sequence to acquire T1-weighted
images before, during, and after IV administration of 0.1mmolkg
–1
Magnevist, infused at 3mls
–1. The DCE time course in the tumour
was analysed on a pixel-by-pixel basis by fitting the data
to the Kety equation and by integrating the area under the initial
(i.e. the first 90s) uptake curve. The contrast-agent concentration
time course in plasma and tissue was inferred from the change in
T1-weighted signal as a function of time. The Kety equation fitted
the tissue contrast-agent time course to a two-compartment model:
dCt/dt¼K
trans(Cp(t)–[Ct(t)/Ve]). Cp and Ct are plasma and tissue
concentration, respectively, K
trans is volume endothelial transfer
constant between plasma and the extracellular extravascular space
(EES), and Ve is fractional EES volume (Ashton et al, 2008).
Blood samples for the evaluation of biomarkers potentially
related to the PDGFR signalling pathway (serum Src homology
phosphatase (SHP)2, phopho(p)-SHP2, pAKT, and pS6) were
collected within 4 days of baseline and on day 14 in each cohort.
Protein levels were analysed using gel electrophoresis
(SDS–PAGE) and the LI-COR immunodetection system with
appropriate antibodies.
Statistical analyses
Sample size was selected empirically: 36–60 patients were considered
required to determine the MTD. Descriptive statistics were used
when analysing patient demographics, safety, and tumour response
data. Paired t-test was used to assess the impact of co-administration
of docetaxel on CP-868,596 pharmacokinetics.
RESULTS
Patient characteristics
Forty-eight patients received at least one dose of study medication.
Patient demographics are summarised in Table 1. The majority of
patients were male, with non-small cell lung cancer (20.8%) and
prostate cancer (12.5%) predominating. Approximately 30% had
received at least three prior therapy regimens. Only four patients
had been treated with docetaxel prior to enrolling into the study.
Drug exposure, DLTs, and expansion DL
DLs tested, DLTs, and median duration of therapy are presented in
Table 2. The median duration on therapy at DLs 1–4 ranged from
1.48 to 5.3 months, the maximum being 12.47 months.
The DLTs for CP-868,596 plus docetaxel were febrile neutrope-
nia, nausea, and vomiting. The DLT for CP-868,596 plus axitinib
and docetaxel was infection associated with febrile neutropenia.
The DL 2 was chosen for expansion as no DLT was observed in the
initial dose-escalation cohort of six patients and this DL combined
the recommended phase 2 dose of CP-868,596 with the most
commonly used dose of docetaxel.
Secondary to an increased incidence of mucositis-like AEs
(mucosal inflammation, oral pain, and/or stomatitis) and neutro-
penia (based on laboratory values and reported AEs), relative to
that expected for docetaxel alone, the planned escalation of the
triplet to CP-868,596 100mg BID/docetaxel 75mgm
–2/axitinib
5mg BID was not attempted. All nine patients in DL 4 had grade
X3 neutropenia (67% grade 4), five had concurrent mucositis-like
AEs, and three had neutropenic fever (33%).
A similar pattern was seen in the doublet cohorts (DLs 1–3), in
which the incidence of neutropenia and mucositis-like AEs
was high. Of 32 patients who received both CP-868,596 and
docetaxel, 94% (30 patients) had grade 3/4 neutropenia and 43%
(13 out of 30) mucositis-like AEs. Five patients, all receiving
75mgm
–2 of docetaxel, had at least one episode of neutropenic
fever (16%).
Treatment discontinuation was required in 41 patients
for progressive disease (26), death (1, progressive disease), AEs
(9), laboratory abnormality (1), and withdrawal of consent (4).
Discontinuation was treatment related in seven patients. Five
patients died during follow-up, four because of progressive disease
and one as a result of a cardiac event (causality unknown).
Safety and tolerability
Treatment-emergent AEs of any causality occurring in 420% of
patients receiving either the double or the triple combination are
shown in Table 3. These were generally of grade 1/2 and reversible.
The most frequently occurring in the doublet DLs included nausea,
diarrhoea, vomiting, constipation, and fatigue. Those of grade 4
Table 1 Baseline demographics
CP-868,596
plus
docetaxel
(n¼39)
CP-868,596 plus
docetaxel
plus axitinib
(n¼9)
Overall
(n¼48)
Age in years, median (range) 55.0 (25–78) 59.0 (31–74) 57 (25–78)
Gender, n (%)
Male 28 (71.8) 9 (100) 37 (77.1)
Female 11 (28.2) 0 11 (22.9)
ECOG performance status, n (%)
0 22 (56.4) 1 (11.1) 23 (47.9)
1 16 (41.0) 7 (77.8) 23 (47.9)
2 1 (2.6) 1 (11.1) 2 (4.2)
Primary diagnosis,n
NSCLC 7 3 10
Prostate cancer 5 1 6
Oesophageal carcinoma 4 1 5
Ewing’s sarcoma 3 0 3
Sarcoma 5 0 5
Small cell lung cancer 3 0 2
Colorectal cancer 3 0 3
Other 9 4 14
Prior cancer therapy
Radiotherapy 27 (69.2) 5 (55.6) 32 (66.7)
Surgery 24 (61.5) 5 (55.6) 29 (60.4)
Chemotherapy 38 (97.4) 9 (100) 47 (97.9)
1 prior regimen 16 (41.0) 5 (55.6) 21 (43.8)
2 prior regimens 9 (23.1) 3 (33.3) 12 (25.0)
X3 prior regimens 13 (33.3) 1 (11.1) 14 (29.2)
Hormonal therapy 7 (17.9) 1 (11.1) 8 (16.7)
Other 4 (10.3) 1 (11.1) 5 (10.4)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; NSCLC¼non-small
cell lung cancer.
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sseverity included neutropenia (grade 4, n¼7; three patients
experienced grade 3 neutropenia) and pulmonary embolism
(grade 4, n¼1; and one patient experienced grade 3 pulmonary
embolism). Expanded safety data (45% incidence) are available
online (Supplementary Table 1).
The most frequent treatment-emergent AEs of any causality in
the triplet DL were hypertension, lethargy, diarrhoea, and fatigue.
Grade 4 AEs comprised febrile neutropenia (grade 4, n¼1;
one patient experienced grade 3 febrile neutropenia), hepatic
encephalopathy (n¼1), and pulmonary embolism (n¼1).
Efficacy
Forty-one patients were evaluable. The best response was stable
disease in 21 patients (51%): 6 out of 7 at DL 1; 5 out of 21 DL 2; 3
out of 6 DL 3; and 7 out of 7 DL 4. Ten patients had stable disease
Table 2 Dosing and DLT summary by patient cohort
Dose
level CP-856,596 Docetaxel Axitinib
Patients
evaluable for
DLT in the
dose-escalation
cohorts
a
Total
number
of
patients DLT (n)
Median
duration
of treatment,
months
(range)
Median
number of
cycles
administered
(range)
Number
of patients
with dose
reduction
1 60mg BID 75mgm
–2 0 6 7 Febrile neutropenia (1) 3.45 (0.23–9.21) 4.0 (1.0–11.0) 0
2 100mg BID 75mgm
–2 0 6 25 Febrile neutropenia (1)
b
Nausea/vomiting (1)
b
1.48 (0.23–8.36) 2.0 (1.0–11.0) 0
3 100mg BID 100mgm
–2 0 6 7 None 2.07 (0.69–4.84) 2.0 (1.0–6.0) 0
4 60mg BID 75mgm
–2 5mg BID 9 9 Klebsiella pneumonae
infection associated with
febrile neutropenia (1)
Febrile neutropenia (1)
5.3 (1.97–12.47) 6.0 (3.0–16.0) 1
Abbreviations: DLT¼dose-limiting toxicity; BID¼twice daily.
aPatients evaluable for DLT either discontinued the study during cycle 1 because of toxicity or completed cycle 1.
bDLT observed in patients enrolled into the expansion cohort.
Table 3 Treatment-emergent (all-causality) AEs of interest experienced by X20% of the study population in either treatment group (all cycles)
a
CP-856,596+docetaxel (n¼39) CP-856,596+docetaxel+axitinib (n¼9)
AE Grade 1/2, n (%) Grade 3/4, n (%) Total Grade 1/2, n (%) Grade 3/4, n (%) Total
Nausea 27 (69.2) 5 (12.8) 32 (82.1) 4 (44.4) 0 4 (44.4)
Diarrhoea 22 (56.4) 3 (7.7) 25 (64.1) 5 (55.6) 0 5 (55.6)
Vomiting 22 (56.4) 1 (2.6) 23 (59.0) 4 (44.4) 0 4 (44.4)
Constipation 20 (51.3) 0 20 (51.3) 4 (44.4) 0 4 (44.4)
Fatigue 11 (28.2) 6 (15.4) 17 (43.6) 4 (44.4) 1 (11.1) 5 (55.6)
Anaemia 10 (25.6) 6
b (15.4) 16 (41.0) 1 (11.1) 0 1 (11.1)
Dyspnoea 10 (25.6) 4 (10.3) 14 (35.9) 4 (44.4) 0 4 (44.4)
Lethargy 10 (25.6) 3 (7.7) 13 (33.3) 5 (55.6) 1 (11.1) 6 (66.7)
Neutropenia 3 (7.7) 10
c (25.6) 13 (33.3) 0 0 0
Pyrexia 11 (28.2) 2 (5.1) 13 (33.3) 4 (44.4) 0 4 (44.4)
Anorexia 11 (28.2) 1 (2.6) 12 (30.8) 2 (22.2) 0 2 (22.2)
Rash
d 12 (30.8) 0 12 (30.8) 3 (33.3) 0 3 (33.3)
Peripheral oedema 11 (28.2) 0 11 (28.2) 0 0 0
Mucosal inflammation 8 (20.5) 1 (2.6) 9 (23.1) 2 (22.2) 2 (22.2) 4 (44.4)
Dysguesia 9 (23.1) 0 9 (23.1) 2 (22.2) 0 2 (22.2)
Pain 6 (15.3) 3 (7.7) 9 (23.1) I (11.1) 0 1 (11.1)
Headache 8 (20.5) 0 8 (20.5) I (11.1) 0 1 (11.1)
Cough 6 (15.4) 0 6 (15.4) 2 (22.2) 0 2 (22.2)
Tachycardia 8 (20.5) 0 8 (20.5) 1 (11.1) 0 1 (11.1)
Febrile neutropenia 1 (2.6) 4 (10.3) 5 (12.8) 0 2
b (22.2) 2 (22.2)
Dehydration 5 (12.8) 0 5 (12.8) 1 (11.1) 1 (11.1) 2 (22.2)
ALT increased 4 (10.3) 0 4 (10.3) 2 (22.2) 0 2 (22.2)
Hypertension 3 (7.7) 0 3 (7.7) 6 (66.7) 0 6 (66.7)
Epistaxis 3 (7.7) 0 3 (7.7) 2 (22.2) 0 2 (22.2)
Peripheral neuropathy 1 (2.6) 0 1 (2.6) 1 (11.1) 1 (11.1) 2 (22.2)
Dysphonia 1 (2.6) 0 1 (2.6) 4 (44.4) 0 4 (44.4)
Lacrimation increased 0 0 0 3 (33.3) 0 3 (33.3)
Abdominal discomfort 1 (2.6) 0 1 (2.6) 2 (22.0) 0 2 (22.0)
Chest pain 3 (7.7) 0 3 (7.7) 2 (22.2) 0 2 (22.2)
Hypotension 3 (7.7) 0 3 (7.7) 1 (11.1) 1 (11.1) 2 (22.2)
Insomnia 4 (10.3) 0 4 (10.3) 2 (22.2) 0 2 (22.2)
PPE 1 (2.6) 0 1 (2.6) 2 (22.2) 0 2 (22.2)
Paraesthesia 3 (7.7) 0 3 (7.7) 2 (22.2) 0 2 (22.2)
Toothache 0 0 0 2 (22.2) 0 2 (22.2)
Abbreviations: AE¼adverse event; ALT¼alanine amino transferase; PPE¼palmar–plantar erythrodysaesthia syndrome.
aThe safety population comprised all patients
who received at least one dose of study medication.
bOne grade 4.
cSeven grade 4.
dPooled data: rash, rash erythematous, rash generalised, rash maculopapular, rash pruritic,
and heat rash.
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slasting 46 months, with a minimum duration of 6.3 months.
Tumour types associated with stable disease 46 months were
prostate (n¼3: 1 each at DLs 1, 2, and 4); sarcoma (n¼3: 1 each at
DLs 1, 3, and 4); NSCLC (n¼2: both DL 4); hepatobiliary (n¼1:
DL 2); and squamous-cell skin carcinoma (n¼1: DL 2). Two
patients who achieved stable disease of 46 months’ duration had
previously been treated with docetaxel: one with sarcoma who
received the triple combination (DL 4) and one with prostate
cancer who was treated with DL 1.
One patient of note, a 39-year-old male with previously treated
metastatic epithelioid sarcoma, illustrated the activity of the
combinations tested. At trial entry, he had disease involving the
skin of the left groin, amputation stump, pubis, as well as pelvic
nodes. He was entered into DL 1. After the first cycle, he noted
reduced erythema and discharge from his cutaneous lesions
and reduced pain. He had persisting stable radiological disease
and came off study after completing the planned six courses.
Within 4 weeks off trial, his skin lesions showed aggressive
progression. Hence, he was retreated with CP-868,596 100mg BID
alone and within 2 weeks his pain again dramatically reduced. A
fluordeoxyglucose positron emission tomography (FDG-PET) scan
confirmed a partial metabolic response (Figure 1A and B). At 2
months, there was clinical improvement in his skin lesions (Figure
1C and D) and stable radiological disease. At 4 months, there was
evidence of early progression and treatment was discontinued.
After a 4-week washout period, during which his skin lesions
flared, he was re-entered into the trial into DL 4 (CP-868,596 60mg
BID/docetaxel 75mgm
–2/axitinib 5mg BID). After two cycles, his
skin lesions stabilised, he achieved a PET partial metabolic
response, and computed tomography (CT) showed a partial
response in the pelvic lymph nodes. After four courses, these
nodes had completely resolved on CT with an ongoing FDG-PET
response; the responses continued on restaging after six courses.
He continued with CP-868,596 plus axitinib alone for a further
3 months until progressing.
Pharmacokinetics
Summary pharmacokinetic data are presented in Table 4. Key
CP-868,596 pharmacokinetic parameters and plasma concentra-
tion profiles were unaffected by co-administration of docetaxel or
docetaxel plus axitinib (Table 4; Figure 2A). Co-administration
of docetaxel had no significant impact on CP-868,596 Cmax
and AUC0–tau, (P40.05, respectively; Table 4). Pharmacokinetic
Figure 1 Dermatologic and metabolic responses in a 39-year-old male with metastatic epithelioid sarcoma. (A) Baseline PET scan. (B) Partial metabolic
PET response following 14 days of CP-868,596 single-agent therapy. (C) Skin lesions prior to and (D) dermatologic response following 35 days of
CP-868,596 single-agent therapy.
Table 4 CP-868,596 pharmacokinetic summary
Pharmacokinetic parameters
Regimens Tmax (h)
Cmax
(ngml
–1)
a
AUC(0–12)
(h ngml
–1)
b
CP-868,596 (100mg BID fed)
N 13 13 13
Mean 2.30 493 3200
Median 1.75 419 2240
CV% 64 86 96
CP-868,596 (100mg BID fed)+docetaxel (75mgm
–2)
N 13 13 13
Mean 2.98 360 2540
Median 3 326 1640
CV% 44 83 89
CP-868,596 (60mg BID fed)+axitinib (5mg BID fed)+docetaxel (75mgm
–2)
N 55 5
Mean 4.4 137 760
Median 1.75 129 654
CV% 111 52 49
Abbreviations: AUC¼area under the curve; BID¼twice daily. CV%¼100% (s.d./
mean).
aCmax: CP-868,596 vs CP-868,596 plus docetaxel: P¼0.055.
bAUCtau (0–12h)
CP-868,596 vs CP-868,596 plus docetaxel: P¼0.117.
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sparameters of CP-868,596 were also unaffected by the co-administra-
tion of axitinib plus docetaxel relative to historical data (Figure 2B).
Axitinib pharmacokinetic parameters were unaffected by co-admin-
istration of CP-868,596 or CP-868,596 plus docetaxel relative to
historical data (Figure 2C). Likewise, docetaxel pharmacokinetic
parameters were not affected by co-administration of CP-868,596 or
CP-868,596 plus axitinib relative to historical data (Figure 2D).
Pharmacodynamics
The DCE-MRI was performed on eight patients in DL 2 (100mg
BID CP-868,596/docetaxel 75mgm
–2), none of whom achieved a
radiological response. There was no treatment effect using
DCE-MRI in these patients as reflected by the median percentage
change at day 14 relative to baseline for the following parameters:
tumour volume, 14.3 (range, 0.0–33.9); vascularised volume, 16.6
(1.4–24.7); perfused AUC,  4.4% ( 40.6–26.1%), and perfused
K
trans, 12.7% ( 26.3–33.3%).
Potential biomarkers of CP-868,596 activity were analysed in 12
patients: six each in DL 1 and DL 2. At day 14, levels of pS6 in
peripheral blood mononuclear cells were significantly decreased
relative to baseline (n¼11; P¼0.021), SHP and pSHP remained
unchanged (n¼10), and levels of pAKT (n¼12) showed a non-
significant increase.
C
P
 
A
U
C
0
–
1
2
 
(
h
 
n
g
–
1
m
l
–
1
)
A
x
i
t
i
n
i
b
 
A
U
C
0
–
1
2
 
(
h
 
n
g
–
1
m
l
–
1
)
2250
2000
1750
1500
1250
1000
750
500
250
0
C
P
 
C
m
a
x
 
(
n
g
 
m
l
–
1
)
400
300
200
100
0
A
x
i
t
i
n
i
b
 
C
m
a
x
 
(
n
g
 
m
l
–
1
)
Axitinib historical Axitinib + CP + docetaxel Axitinib historical Axitinib + CP + docetaxel
80
60
40
20
0
D
o
c
e
t
a
x
e
l
 
c
l
e
a
r
a
n
c
e
 
(
l
 
 
h
–
1
 
m
–
2
)
Docetaxel historical Docetaxel + CP Docetaxel + CP + axitinib
40
35
30
25
20
15
10
5
0
450
400
350
300
250
200
150
100
50
0
CP historical CP + axitinib + docetaxel CP historical CP + axitinib + docetaxel
C
P
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
n
g
 
m
l
–
1
)
1000
100
10
1
CP alone 100 mg BID
CP 100 mg BID + docetaxel
CP 60 mg BID + axitinib + docetaxel
Time (h)
02468 1 0 1 2 1 4
Figure 2 (A) Serum concentration profiles of CP-868,596 (CP) when administered alone or in combination with axitinib or axitinib and docetaxel.
Reference data for single-agent CP-868,596 are derived from Lewis et al (2009). (B, C) Pharmacokinetic parameters of 60mg CP-868,596 (CP) and axitinib
when administered alone or in triple combination with docetaxel. Reference data for single-agent CP-868,596 are derived from Lewis et al (2009) and Pfizer
data on file. Reference data for single-agent axitinib are derived from Rugo et al (2005). (D) Clearance of docetaxel when administered alone and in
combination with CP-868,596 (CP) and CP-868,596 plus axitinib. Reference data for single-agent docetaxel are derived from Bruno and Sanderink (1993)
and Bruno et al (1996).
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sDISCUSSION
The concurrent modulation of TIH together with tumoural
angiogenesis may be an approach to achieve adequate cytotoxic
drug exposure and increase therapeutic efficacy. In order to
understand the clincial effects of combining PDGFR inhibition
with chemotherapy, this phase Ib trial investigated the combina-
tion of CP-868,596 and docetaxel in cancer patients. Also explored
was the effect of concurrently inhibiting PDGFR and VEGFRs by
adding axitinib, a potent inhibitor of VEGFR, to this combination.
The tested regimens were well tolerated and the combination
of the recommended phase II dose of CP-868,596 (100mg BID
with food) (Lewis et al, 2009) with docetaxel (100mgm
–2 every
3 weeks) was feasible. However, dose escalation was limited for
the triple combination because of the increased incidence of
concurrent mucositis-like AEs and neutropenia relative to that
expected for docetaxel alone.
The most common toxicities to date for CP-868,596 are nausea,
vomiting, diarrhoea, and transaminitis (Lewis et al, 2009). For
axitinib, the main toxicities are fatigue, nausea, diarrhoea, and
hypertension (Rugo et al, 2005). Hence, together with the toxicities
of docetaxel (Sanofi-Aventis U.S.LLC, 2008), none of the frequently
observed treatment-related AEs in this study were unexpected in
type. As the toxicity profiles of CP-868,596 and axitinib are largely
non-overlapping, it was, therefore, assumed that they might
be co-administered without additive toxicity. Unexpectedly, the
incidence of concurrent mucositis-like AEs and neutropenia was
elevated as noted above.
None of the patients entered in this trial achieved a major
radiological response, an observation similar to that reported for
the single-agent phase I study of CP-868,596 (Lewis et al, 2009).
Nevertheless, it was unanticipated given that docetaxel is an active
agent for the majority of advanced malignancy types entered into
this trial (Burris et al, 1993; Extra et al, 1993; Tomiak et al, 1994).
The lack of radiological response was also unanticipated as
CP-868,596 was expected to increase the intratumoural docetaxel
concentration. The effects of PDGFR inhibition on intratumoural
IFP and intratumour drug concentrations were not measured in
this study. However, in preclinical xenograft models, concomitant
administration of PDGFR antagonists increased the tumoural
uptake of paclitaxel (Pietras et al, 2002), and liposomal doxo-
rubicin (Vlahovic et al, 2007), with increased antitumour efficacy
(Vlahovic et al, 2007).
The lack of objective radiological response may reflect the small
sample size given that the study’s major end point was safety and
toxicity based. It may also reflect the extent of prior chemotherapy
undergone by patients entered and the heterogeneity of their
disease. A recent phase II study treated patients with NSCLC
(n¼18) with second-line imatinib (a non-selective PDGFR
inhibitor) plus docetaxel and reported a partial response rate of
5.5% and stable disease in 27.8% of patients (Huang et al, 2008).
Similarly, low response rates were observed in which imatinib was
combined with capecitabine in metastatic breast cancer (Chew
et al, 2008). The selection of patients whose tumours are known to
be driven by PDGFR may optimise response rates. In an in vitro
study of PDGFR-b overexpressing mesothelioma cell lines,
imatinib induced cytotoxicity and apoptosis, probably because of
PDGFR-b inactivation and downstream AKT pathway inhibition
(Wilmink and Richel, 2008).
The triple combination cohort was notable in that all seven
evaluable patients achieved stable disease and all nine remained on
therapy for a median of six cycles (range 3–16). Phase I trials
of comparable doses of single-agent docetaxel reported a median
of three–four cycles of administered therapy (Bissett et al, 1993;
Tomiak et al, 1994). Thus, this study suggests that the combination
of docetaxel with CP-868,596 and axitinib resulted in a regimen
with improved disease control and tolerability. However, improved
disease control may be due to the combination of axitinib with
docetaxel.
Pharmacokinetic and pharmacodynamic parameters were also
assessed. Pharmacokinetic data showed a lack of drug–drug
interactions; indicating the feasibility of both the double and triple
combinations from a pharmacokinetic perspective. Preliminary
DCE-MRI data for eight patients who received CP-868,596 plus
docetaxel showed no evidence of a treatment effect: this is not
surprising given the lack of response observed. It may also,
however, reflect the small sample size and the heterogeneity of
tumour types in the study population. These findings do not
corroborate the DCE-MRI changes observed on treatment with
CDP860, a di-Fab anti-PGDF antibody, although the MRI
parameter assessments were not identical (Jayson et al, 2005). In
the study reported here, it is possible that tumoural CP-868,596
exposure was sub-optimal or that the MRI parameters assessed
failed to detect vascular changes arising from PDGFR inhibition.
Further studies are required to determine whether CP-868,596 can
be combined with other anticancer drugs and whether efficacy can
be improved with the use of potential biomarkers of response such
as PDGFR expression.
In conclusion, combination therapy with CP-868,596 and
docetaxel was well tolerated and no unfavourable drug–drug
interactions were shown. The expected additive clinical efficacy
was not observed and may not support the clinical development of
this combination in non-selected patient populations. However,
the addition of axitinib to the combination resulted in greater-
than-expected benefits in terms of prolonged stable disease and
tolerability. The separate inhibition of individual receptor targets
in this study resulted in unexpected findings, suggesting that this
approach may be worthy of further study.
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